



WORLD ECONOMIC FORUM



Technology
Pioneer
2007

NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX: AMF

AMORFIX LIFE SCIENCES DEVELOPS TWO VACCINES THAT EXTEND LIFE IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) ANIMAL MODEL

TORONTO, Ontario – October 9, 2007 – Amorfix Life Sciences (TSX: AMF), a company focused on treatments and diagnostics for brain-wasting diseases, today announced that it will be presenting the results from its vaccine development program for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig's disease, at the 132nd Annual Meeting of the American Neurological Association today in Washington, DC. The vaccine approach, also known as active immunization, is the second therapeutic approach for which proof-of-concept has been established by Amorfix for the treatment of ALS this year. In March, Amorfix established a passive immunization approach in the same mouse model of ALS by injecting monoclonal antibodies that target the misfolded superoxide dismutase 1 (SOD1) protein.

The paper entitled "Active and Passive Immunization of SOD1 Disease Specific Epitopes in a Mouse Model of Amyotrophic Lateral Sclerosis" will be presented by Dr. Neil Cashman, the Chief Scientific Officer of Amorfix. The study shows for the first time life extension in a mouse model of ALS using two vaccines targeted at different regions of the protein, termed disease-specific epitopes, found only on the molecular surface of misfolded SOD1.

"These results support our original belief that specifically targeting misfolded proteins using immunotherapies may lead to an effective treatment for this debilitating disease, and by extension numerous other diseases such as Parkinson's and Alzheimer's diseases," said Dr. George Adams, CEO of Amorfix Life Sciences.

Amorfix's targeted vaccine approach is based on the premise that the misfolding and aggregation of SOD1, which is known to occur in familial ALS patients, is a principal agent in the death of motor neurons in all types of ALS disease. Amorfix believes that by administering a vaccine designed to elicit the production of antibodies that target only misfolded SOD1, the immune system could be educated to specifically recognize misfolded SOD1 as foreign and neutralize it, while sparing the normally folded protein from autoimmune recognition.

In 2006, Amorfix and Biogen Idec entered into a research and investment agreement that includes an option for Biogen Idec to license the exclusive worldwide rights to Amorfix's biotherapeutics for ALS.

In other news, Amorfix would like to thank Don McCaffrey for serving as a Director of the Company and Chair of the Compensation Committee for the last 2 years. "Don joined the Board on the public listing of the Company and his significant contributions have immeasurably assisted the Company to build value over his term," said Graham Strachan, Chair of the Board.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- 30 -

For more information, please contact:

| | |
|--|---|
| <p>Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3813 Fax: (416) 482-3811 george.adams@amorfix.com</p> | <p>James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3814 Fax: (416) 482-3811 james.parsons@amorfix.com</p> |
|--|---|